(Q44213168)

30 November 2017

Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy (English)

1 reference

30 November 2017

0 references

congestive heart failure

1 reference

Michel F Rousseau

1

1 reference

30 November 2017

Olivier Gurné

2

1 reference

30 November 2017

Daniel Duprez

3

1 reference

30 November 2017

Walter Van Mieghem

4

1 reference

30 November 2017

Annie Robert

5

1 reference

30 November 2017

Sylvie Ahn

6

1 reference

30 November 2017

Laurence Galanti

7

1 reference

30 November 2017

Jean Marie Ketelslegers

8

1 reference

30 November 2017

Belgian RALES Investigators

9

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Journal of the American College of Cardiology

30 November 2017

1 reference

30 November 2017

40

1 reference

30 November 2017

9

1 reference

30 November 2017

1596-1601

1 reference

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Aldosterone and vascular damage

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

1 reference

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Aldosterone in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Inhibition of myocardial endothelin pathway improves long-term survival in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Aldosterone blunts the baroreflex response in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Renin expression at sites of repair in the infarcted rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Aldosterone production is activated in failing ventricle in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902382-3

7 January 2021

10.1016/S0735-1097(02)02382-3

Identifiers

DOI

1 reference

30 November 2017

1 reference